1. Introduction {#s0005}
===============

Gliomas comprise 27% of all brain tumours and 80% of all malignant brain tumours ([@bb0080]). The World Health Organisation (WHO) glioma classification system dichotomises the tumours to low-grade glioma (LGG) comprising of histological grades I and II tumours and high-grade glioma (HGG) comprising of histological grades III and IV tumours ([@bb0105]; [@bb0125]). Recent revision of the WHO guidelines incorporates molecular parameters alongside the histology in the classification of tumour entities ([@bb0125]). The complexity of the disease is often aggravated by tumour proliferation, localized invasion, metastasis, resistance to therapy ([@bb0175]), and different responses to treatments among patients due to variation in genetic profiles of the tumours ([@bb0065]; [@bb0155]).

Magnetic resonance imaging (MRI) is the generally preferred modality for brain imaging as it offers valuable information on overall tumour structure, composition, physiology and function ([@bb0075]). Tumour characteristics such as intensity distribution, enhancement, size, shape, structure, location, volume, border, focality, subventricular zone involvement, cystic changes, percentage of necrosis, and tumour volume are the conventional imaging parameters investigated for glioma characterisation ([@bb0110]; [@bb0190]; [@bb0070]; [@bb0140]; [@bb0035]). However, clinical translation using only conventional imaging assessments is difficult due to the heterogeneous nature of the tumours.

The detection and staging of glioma at an early stage are essential for early intervention to improve prognosis and minimize neurocognitive risks. Heterogeneity in neuroimaging, pathologic and molecular features had been the main existing problem for glioma diagnosis ([@bb0070]). The determination of the grades and subtypes are challenging due to diverse characteristics, even within a single tumour. Tumour heterogeneity further complicates histopathological observations and interferes with treatment decisions and clinical management. Histopathology tests serve as the gold standard for glioma diagnosis but its usefulness is limited by several drawbacks such as high invasiveness, risk of infection and bleeding, subjected to inter- and intra-pathologists variability, and possibility of sampling error. Thus, there is a need for fast and non-invasive imaging biomarkers that could elucidate the underlying inter- and intra-tumoural histopathological changes.

An increased rate of lipid synthesis has long been recognised as an important characteristic in tumorigenesis. However, the contribution of lipids to the transformation, development, and progression of tumour are still not yet fully understood ([@bb0010]). Lipids such as mobile fatty acids, triglycerides, phospholipids, cholesterol esters, sphingolipid, prostaglandins and steroid hormones serve as important components in necrosis ([@bb0040]), cellular membrane breakdown, ([@bb0115]) and signal transduction. Lipogenesis is one of the main metabolism pathways regulated to sustain rapid tumour growth. Elevated lipid levels had been found to correspond with higher tumour grades and aggressiveness in characterisation of brain tumours ([@bb0060]; [@bb0160]; [@bb0120]). The alteration in lipid levels of the brain is postulated to be due to the cell membrane perturbation induced by apoptosis and necrosis ([@bb0160]; [@bb0195]; [@bb0020]).

In-and opposed-phase (IOP) imaging is another alternative for lipid quantification other than magnetic resonance spectroscopy (MRS). The mechanism behind IOP imaging is the difference in resonance frequency between proton nuclei from water and fat content of the tissues. Water and fat experienced a slight difference in magnetic field strengths due to different chemical environments and surrounding electron density. IOP imaging has been used clinically for lipid detection in disorders such as adrenal adenoma, renal angiomyolipoma, and bone marrow pathology ([@bb0090]; [@bb0145]; [@bb0170]; [@bb0135]). Recent usage is seen for detection of mobile lipids in intracranial lesions, including glioma ([@bb0160]; [@bb0120]). The advantage of IOP imaging is that it provides an overall evaluation of lipid quantification of the tumour as compared to the smaller sampling area provided by MRS.

In this work, we aim to understand the lipid landscape of glioma. Different tumour regions were delineated using semi-automatic segmentation method. By providing the lipid map, we relate with conventional imaging components to advance our understanding of glioma heterogeneity.

2. Materials and methods {#s0010}
========================

2.1. MRI data retrieval and review {#s0015}
----------------------------------

This was a retrospective study of a prospectively collected pre-operative imaging data from 40 histologically proven glioma cases treated at our centre between December 2010 and October 2017. This study was approved by our institutional ethics board and all patients provided written informed consent. The glioma patients were subjected to MRI scanning using a 3 T MRI scanner (Signa HDx, General Electric, USA). All of them underwent brain tumour protocol, including T1-weighted (T1), T2-weighted (T2), post-contrast T1-weighted, diffusion-weighted imaging (DWI) with derived apparent diffusion coefficient (ADC), and additional chemical shift IOP sequence. The IOP imaging parameters were: 150 ms repetition time, 2.4 ms echo time for the in-phase, 5.8 ms echo time for the opposed-phase, flip angle of 80°, the number of averages is 1, 250 mm × 250 mm field of view, the matrix size was 256 × 256 and 5 mm slice thickness. The inclusion criteria for the study were: 1) histologically proven glioma (grade II-IV), and 2) availability of MRI images in IOP.

2.2. Delineation of tumour regions {#s0020}
----------------------------------

The regions of tumour (solid enhancing, solid non-enhancing, and cystic) were delineated on post-contrast T1 images using a semi-automated segmentation approach, i.e. snake model implemented in ITK-SNAP ([@bb0205]) with reference to structural MRI images (pre- and post-contrast T1, T2, and FLAIR) and diffusion images (ADC and DWI). The definition of the tumoural regions are described in [Table 1](#t0005){ref-type="table"} and the examples of the MRI images used for identification of tumoural regions are shown in [Fig. 1](#f0005){ref-type="fig"}. The tumour regions was segmented by a single user (PS) and the tumoural region masks was then verified by an experienced neuroradiologist (NR).Table 1The definition of the tumoural regions in different MRI sequences in reference to grey matter.Table 1Tumour regionsMRI sequencesSignal comparisonSolid-enhancingT1Iso to hypointensepost-contrast T1HyperintenseSolid non-enhancingT1Iso to hypointenseT2Iso to hyperintenseADCIso to hypointenseCysticT1HypointenseT2Homogenous hyperintense areasDWI & ADCIsointense to CSF[^1]Fig. 1The identification of tumour regions using different MRI sequences of a GBM patient. a) The pre-contrast T1 image, b) post-contrast T1 image where the solid enhancing region is the enhancing rim, c) T2 image, d) apparent diffusion coefficient (ADC) image with the blue arrow in ADC showed the cystic region while orange arrows depicted the solid non-enhancing region of the tumour and, f) diffusion-weighted image (DWI).Fig. 1

2.3. Image post-processing of the lipid maps and tumour region masks {#s0025}
--------------------------------------------------------------------

The presence of lipid or percentages of fat is reflected by the quantification of relative signal loss in the in-phase and opposed-phase images, also termed the signal loss ratio (SLR) as defined in the following Eq. (26):$$\mathbf{SLR} = \frac{\mathbf{signal}_{\mathbf{in}} - \mathbf{signal}_{\mathbf{opp}}}{\mathbf{signal}_{\mathbf{in}}}$$where ***signal***~***in***~ is the in-phase signal while ***signal***~***opp***~ is the opposed-phase signal. The lipid map is a two-dimensional visualization of the SLR.

Image processing of the images and masks was performed using SPM12 (Statistical Parametric Software) ([@bb0200]) implemented in MATLAB ([@bb0130]). The lipid maps were first skull-stripped for brain extraction followed by the registration of the structural T1, lipid maps, and tumour region masks to standard MNI152 space (MNI152 is a template brain/space from Montreal Neurological Institute, stored within FSL (FMRIB Software Library) ([@bb0045]) ([Fig. 2](#f0010){ref-type="fig"}). The T1 images were then co-registered to in- and opposed-phase images. Blood vessels and capillaries were subtracted from the lipid map as they affect signal intensities. The mean SLR values of the regions were obtained by overlaying the region masks onto the lipid maps with reference to the co-registered T1 images.Fig. 2The pre-processed images of a GBM patient. a) The raw T1 MRI image, b) in-phase sequence, c) opposed-phase sequence, d) skull stripped and co-registered lipid map, the co-registered masks (delineated in red) of e) solid enhancing region, f) solid non-enhancing region, and g) cystic region of the tumour.Fig. 2

2.4. Statistical analysis {#s0030}
-------------------------

Kruskal-Wallis test was carried out to establish significant differences in SLR of the tumour regions across the WHO grades. The statistical significant difference was declared at *p* \< .05. The Spearman correlation test was performed to test the correlation between the mean SLR values and the tumour regions.

3. Results {#s0035}
==========

[Table 2](#t0010){ref-type="table"} shows the demographics of the glioma patients across the WHO tumour grades. The distribution of the SLR of solid non-enhancing region of the tumour demonstrated significant difference across the three grades (*p* \< .01; [Table 3](#t0015){ref-type="table"}) where increased SLR values were seen with increasing tumour grades ([Fig. 3](#f0015){ref-type="fig"}). Multiple comparisons between the different grades with correction showed significant difference between grade II and IV (*p* \< .001) ([Table 4](#t0020){ref-type="table"}). The lipid map in grade IV (GBM) showed higher extent of morphologic heterogeneity whereas lipid maps of low-grade gliomas were more homogeneous ([Fig. 4](#f0020){ref-type="fig"}). Increased heterogeneity was shown as positive skewness of all the grades in solid non-enhancing regions (skewness: G~II~ = 0.98, G~III~ = 0.16 & G~IV~ = 0.24). The solid enhancing and cystic regions showed negative skewness in grade III. A higher SLR value was seen from the lipid map in high-grade glioma, as shown as regions indicated in red. The lipid maps with tumour regions overlaid onto them were shown in [Fig. 4](#f0020){ref-type="fig"} for different WHO grades. A strong positive correlation was seen between WHO grades with mean SLR on lipid map of solid non-enhancing region (*ρ*=0.68, *p* \< .001).Table 2Patients demographics across the tumour grades.Table 2Clinical parametersWHO grade (*n* = 40)G~II~ (*n* = 14)G~III~ (*n* = 8)G~IV~ (*n* = 18)Age (mean, (range))37.36 (16--63)46.13 (25--71)51.78 (10--73)GenderMale7 (50%)5 (62.5%)10 (55.6%)Female7 (50%)3 (37.5%)8 (44.4%)Histology typeDiffuse astrocytoma500Pilomyxoid astrocytoma100Pleomorphic xanthoastrocytoma100Gemistocystic astrocytoma100Fibrillary astrocytoma100Oligoastrocytoma100Oligodendroglioma410Anaplastic oligodendroglioma050Anaplastic astrocytoma020Glioblastoma multiforme (GBM)0017Pontine GBM001Tissue samplingTotal / partial resection12814Stereotactic biopsy204Tumour regionsWith solid enhancing region12 (85.7%)4 (50%)18 (100%)With solid non-enhancing region13 (92.9%)8 (100%)17 (94.4%)With cystic region9 (64.3%)5 (62.5%)14 (77.8%)Table 3Descriptive data presented as the mean and standard deviation (SD) of the SLR values across WHO tumour grades.Table 3MarkersWHO gradeKruskal-Wallis testMean (SD)SLRG~II~ (*n* = 12)G~III~ (n = 4)G~IV~ (n = 18) Solid enhancing0.074 (0.058)0.073 (0.021)0.075 (0.015)0.131SLRG~II~ (*n* = 13)G~III~ (n = 8)G~IV~ (*n* = 17) Solid NE0.043 (0.017)0.061 (0.028)0.080 (0.019)\<0.01[⁎](#tf0005){ref-type="table-fn"}SLRG~II~ (*n* = 9)G~III~ (*n* = 5)G~IV~ (n = 14) Cystic0.080 (0.092)0.059 (0.022)0.061 (0.018)0.469[^2][^3]Fig. 3The SLR distributions across the WHO grades. The boxplots showing distributions of SLR in the solid non-enhancing region of the tumour across the WHO grades. NE: non-enhancing.Fig. 3Table 4The multiple comparisons between the grades (II, III, & IV) for solid non-enhancing region of tumour.Table 4Group comparisonTest statisticStandard errorStandard Test statisticSignificanceAdjusted significanceII-III−6.434.99−1.290.1980.593II-IV−16.664.09−4.07\>0.001[⁎](#tf0010){ref-type="table-fn"}\>0.001[⁎](#tf0010){ref-type="table-fn"}III-IV−10.234.77−2.150.0320.095[^4]Fig. 4The structural and diffusion MRI images, tumour regions and lipid maps for three glioma patients of different grades (Grade II, III and IV). Examples of MRI images describes the T1, T2, ADC, semi-automatically segmented tumoural masks of the different regions (solid-enhancing, solid non-enhancing and cystic regions) overlaid onto the T1-W images, in-phase and opposed phase, the constructed lipid map with overlaid tumour region masks, and pseudo-colour lipid map displaying the lipid distribution of the brain for visualization purpose, of A) gemistocytic astrocytoma (grade II), B) anaplastic oligodendroglioma (grade III) and C) GBM (grade IV).Fig. 4

4. Discussion {#s0040}
=============

In this study, we performed lipid mapping based on IOP MRI images, to landscape the lipid distribution of different grades of glioma. We postulated that the alteration of the structural lipid quantification obtained from lipid mapping could be attributed to the topographical distribution of the lipid molecules resulting from reprogramming of lipid metabolism. Our work is an initial attempt to understand the multifaceted landscape in terms of lipid distribution and microenvironment heterogeneity in gliomatous tumours. This work presents an improvement and extension of our earlier study on lipid quantification and glioma grading ([@bb0160]). The improvement was carried out in three areas. Firstly, the current 3D ROI construction of the tumour regions implemented using a semi-automatic segmentation approach offers a more objective and consistent acquisition of the mean SLR values. Second, lipid quantification was evaluated in a more detailed manner by separating the solid region of the tumour into enhancing and non-enhancing regions. Finally, the SLR is presented in a 2D distribution (i.e. the lipid map) to better visualise lipid distribution in relation to the tumour morphology and glioma grades.

Our study showed that mean SLR of the solid non-enhancing region of the tumour is useful for discrimination of the tumour grades compared to solid-enhancing and cystic regions. The solid non-enhancing region of the tumour is more homogeneous than the solid enhancing and cystic regions. This region has more blood vessels (likely a combination of normal and newly formed vessels from neovascularization) where extravasation of blood plasma and contrast agents into the extravascular extracellular space occur due to blood-brain barrier (BBB) breakdown ([@bb0005]; [@bb0095]); resulting in both intravascular enhancement and extravasation-related enhancement. The non-enhancing region of the tumour may harbour extracellular lipids from broken cellular membranes secondary to deficient blood perfusion, i.e. the opposite situation with the enhancing region. The lipid distribution at the non-enhancing region is better at differentiating glioma grades and may reflect the true aggressiveness of the tumoural tissues. Although lipid distributions (percentage of fat) are highest in the solid enhancing regions, they do not show any discriminating ability in this study as shown as the closeness of the mean SLR values across the grades. The lipid map outcome shows that the solid non-enhancing region of the tumour has the highest yield in the differentiation of glioma grading and therefore provides the best site for biopsy.

The SLR values in the lipid map reflect lipids fraction that arise from the lipid components in brain tissues. The lipid composition of the brain tissues offers insights about histological cell type, state of cellular growth, maturation, and differentiation ([@bb0030]), thus providing useful information for diagnosis and prognosis. The increase in lipid biosynthesis has been long recognised as an essential element of the metabolic reprogramming in cancer cells aside from glucose and glutamine metabolism ([@bb0010]; [@bb0060]; [@bb0165]). The metabolite reprogramming supports rapid proliferation of cancer cells to fulfill the increased demand for energy and nutrients. The alteration of visible lipids has been attributed to cellular processes such as proliferation, inflammation, malignancy, growth arrest, necrosis, apoptosis, migration, and invasion ([@bb0010]; [@bb0055]). High expression of lipids is contributed by the prompt release from storage for cell growth and biological membranes generation, the breakdown of cellular membrane structure in response to growth stimuli resulting from malignant cell transformation, and increased numbers of cytoplasmic vesicles ([@bb0010]; [@bb0060]; [@bb0055]).

The delineation of the brain tumour by manual segmentation provides essential distinction between lesions and normal tissues. Manual delineation of tumour is not only tedious and time-consuming but also subjected to intra- and inter-observer variability. This potentially leads to substantial inconsistency in the delineation of the region of interest (ROI). Furthermore, manual segmentation is limited by reproducibility and feasibility in labelling large cohorts of patients in clinical environment. These problems can be addressed by engaging automatic segmentation methods. The semi-automatic approach used in this study is a better way for delineation of the tumour regions as it is less time consuming and less dependent to observer\'s judgement. This method is applicable to the clinical practice where user interaction only requires the placement of the initial contour at the area of tumour regions.

Few limitations of this study include small sample size due to relatively quick progression of grade III to grade IV tumour and acquisition artefacts especially lesions near the air and bone interface. The IOP imaging clinically available in our study, is also known as Dixon method, and the measurement of SLR in this study is related to the two-point Dixon method used to separate fat and water signals ([@bb0025]; [@bb0100]). Unfortunately, this approach is also sensitive to off-resonance effects that arise from magnetic field inhomogeneity ([@bb0100]). The magnetic susceptibility effects are pronounced especially in near air tissue-boundaries, implants, and iron depositions ([@bb0145]). The three-point Dixon method acquires three imaging phases so that each acquisition occurs at a different phase between the water and fat signals ([@bb0150]). It has advantage of taking into account for magnetic field inhomogeneities but requires longer acquisition time compared to two-point Dixon method. Future work can be extended into the application of Iterative Decomposition with Echo Asymmetry and Least Squares Estimation (IDEAL), a robust reconstruction algorithm generalised from Dixon method that takes into account the transverse relaxation and intra-voxel dephasing effects ([@bb0015]; [@bb0085]). IDEAL combines asymmetrically acquired echoes with an iterative least-squares decomposition algorithm to achieve maximum signal noise ratio in addressing issues related to magnetic field inhomogeneities ([@bb0185]). Other factors that might affect the SLR values include blood flow, blood volume, haemorrhage, and susceptibility artefacts.

5. Conclusion {#s0045}
=============

Lipid quantification using lipid distribution mapping with use of conventional imaging showed potential as a diagnostic tool, by providing sites for maximal differentiation in the grading of glioma. SLR value obtained from the lipid map is also a feasible imaging biomarker that can be used to reflect the lipid landscape of the glioma microenvironment. The knowledge accrued provides the basis for understanding the underlying tumoral histopathological changes that occur in the tumour regions and tumour development.
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[^1]: CSF: cerebrospinal fluid.

[^2]: NE: non-enhancing.

[^3]: *p*-values \<.01.

[^4]: Asymptotic significances (2-sided tests) are displayed. The significance level is 0.05. Significance values have been adjusted by the Bonferroni correction for multiple tests.
